未治療の局所進行切除不能または転移性 PD-L1 選択非小細胞肺癌患者におけるアテゾリズマブとの併用でのチラゴルマブとアテゾリズマブとの併用でのプラセボと比較した研究 (SKYSCRAPER-01)
以前に未治療の局所進行切除不能または転移性 PD-L1 選択非切除患者におけるアテゾリズマブとの併用におけるプラセボと比較した、アテゾリズマブとの併用における抗痙攣抗体であるティラゴルマブの第 III 相、無作為化、二重盲検、プラセボ対照研究-小細胞肺がん
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Colorado
-
Denver、Colorado、アメリカ、80220
- Rocky Mountain Cancer Center - Denver
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- Yale Cancer Center
-
-
Florida
-
St. Petersburg、Florida、アメリカ、33705
- SCRI Florida Cancer Specialists North
-
Tallahassee、Florida、アメリカ、32308
- SCRI Florida Cancer Specialists PAN
-
-
Minnesota
-
Saint Paul、Minnesota、アメリカ、55102
- US oncology research at Minnesota Oncology
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- SCRI Oncology Partners
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- Virginia Cancer Specialists (Fairfax) - USOR
-
Salem、Virginia、アメリカ、24153
- Onc & Hem Assoc SW Virginia
-
-
-
-
Campania
-
Naples、Campania、イタリア、80131
- Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
-
-
Lazio
-
Rome、Lazio、イタリア、00151
- Azienda Ospedaliera San Camillo Forlanini
-
Rome、Lazio、イタリア、00168
- Policlinico Universitario "Agostino Gemelli"
-
-
Lombardy
-
Milan、Lombardy、イタリア、20141
- Irccs Istituto Europeo di Oncologia (IEO)
-
Monza、Lombardy、イタリア、20900
- Asst Di Monza
-
Rozzano、Lombardy、イタリア、20089
- Istituto Clinico Humanitas
-
-
Piedmont
-
Orbassano、Piedmont、イタリア、10043
- Azienda Sanitaria Ospedaliera S Luigi Gonzaga
-
-
Umbria
-
Perugia、Umbria、イタリア、06156
- Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
-
-
Veneto
-
Padova、Veneto、イタリア、35128
- IOV - Istituto Oncologico Veneto - IRCCS
-
-
-
-
-
Kryvyi Rih、ウクライナ、50048
- ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
-
Uzhhorod、ウクライナ、88000
- Uzhgorod Nat. University Central Municip Hosp
-
-
-
-
-
's-Hertogenbosch、オランダ、5223 GZ
- Jeroen Bosch Ziekenhuis
-
Ede、オランダ、6716 RP
- Ziekenhuis Gelderse Vallei
-
Leeuwarden、オランダ、8934 AD
- Frisius MC Leeuwarden
-
The Hague、オランダ、2545 AA
- Hagaziekenhuis, locatie Leyweg
-
-
-
-
Queensland
-
Woolloongabba、Queensland、オーストラリア、4102
- Princess Alexandra Hospital
-
-
Victoria
-
Heidelberg、Victoria、オーストラリア、3084
- Austin Hospital Olivia Newton John Cancer Centre
-
Melbourne、Victoria、オーストラリア、3000
- Peter Maccallum Cancer Centre
-
-
-
-
-
Linz、オーストリア、4020
- Ordensklinikum Linz Elisabethinen
-
Vienna、オーストリア、1140
- Klinik Penzing
-
Vienna、オーストリア、1210
- Krankenhaus Nord - Klinik Floridsdorf
-
-
-
-
-
Athens、ギリシャ、185 47
- Metropolitan Hospital
-
Athens、ギリシャ、104 31
- Sotiria Hospital
-
Larissa、ギリシャ、411 10
- University Hospital of Larissa
-
Thessaloniki、ギリシャ、570 01
- Diavalkaniko Hospital
-
-
-
-
-
Bern、スイス、3010
- Inselspital Bern
-
Lausanne、スイス、1011
- CHUV
-
Sankt Gallen、スイス、9000
- HOCH Health Ostschweiz, Kantonsspital St. Gallen
-
-
-
-
-
Madrid、スペイン、28041
- Hospital 12 de Octubre
-
Madrid、スペイン、28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Madrid、スペイン、41013
- Hospital Universitario Virgen del Rocío
-
Málaga、スペイン、29010
- Hospital Regional Universitario de Malaga
-
Zaragoza、スペイン、50009
- Hosp Clinico Univ Lozano Blesa
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- Hospital Universitario Germans Trias i Pujol
-
-
-
-
-
Belgrade、セルビア、11000
- Clinical Center of Serbia
-
Belgrade、セルビア、11080
- University Hospital Medical Center Bezanijska kosa
-
-
-
-
-
Bangkok、タイ、10330
- Chulalongkorn Hospital
-
Bangkok、タイ、10400
- Ramathibodi Hospital
-
Bangkok、タイ、10700
- Faculty of Med. Siriraj Hosp.
-
Songkhla、タイ、90110
- Songklanagarind Hospital
-
-
-
-
-
Adana、トルコ(Türkiye)、01120
- Adana Baskent University Hospital
-
Ankara、トルコ(Türkiye)、06100
- Hacettepe University Medical Faculty
-
Istanbul、トルコ(Türkiye)、34098
- Istanbul University Cerrahpasa Faculty of Medicine
-
Izmir、トルコ(Türkiye)、35110
- Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
-
Kadiköy、トルコ(Türkiye)、34722
- Goztepe Prof.Dr. Suleyman Yalcin City Hospital
-
Malatya、トルコ(Türkiye)、44280
- Inonu University Medical Faculty of Medicine
-
-
-
-
-
Frankfurt、ドイツ、60488
- Krankenhaus Nordwest
-
Großhansdorf、ドイツ、22927
- LungenClinic Großhansdorf GmbH
-
Halle、ドイツ、06120
- Krankenhaus Martha-Maria Halle-Doelau gGmbH
-
Immenhausen、ドイツ、34376
- Fachklinik für Lungenerkrankungen
-
Löwenstein、ドイツ、74245
- SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
-
Münster、ドイツ、48153
- Gemeinschaftspraxis für Hämatologie und Onkologie
-
Stuttgart、ドイツ、70376
- Klinik Schillerhöhe
-
-
-
-
-
Budapest、ハンガリー、1121
- Orszagos Koranyi TBC es Pulmonologiai Intezet
-
Mátraháza、ハンガリー、3233
- Matrai Gyogyintezet
-
Szolnok、ハンガリー、5004
- Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
-
-
-
-
Rio Grande do Sul
-
Ijuí、Rio Grande do Sul、ブラジル、98700-000
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
-
-
São Paulo
-
Barretos、São Paulo、ブラジル、14784-400
- Hospital de Cancer de Barretos
-
-
-
-
-
Arequipa、ペルー、5154
- Instituto Regional de Enfermedades Neoplásicas del Sur
-
Lima、ペルー、15038
- Instituto Nacional de Enfermedades Neoplasicas
-
Lima、ペルー、Lima 41
- Clinica Internacional, Sede San Borja
-
San Isidro、ペルー、Lima 27
- Clinica Ricardo Palma
-
-
-
-
-
Gda?sk、ポーランド、80-214
- Uniwersyteckie Centrum Kliniczne
-
Olsztyn、ポーランド、10-357
- Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
-
Poznan、ポーランド、60-569
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
-
-
-
-
Mexico CITY (federal District)
-
México、Mexico CITY (federal District)、メキシコ、06100
- Cryptex Investigacion Clinica SA de CV
-
-
Nuevo León
-
Monterrey、Nuevo León、メキシコ、64710
- AVIX Investigación Clínica S.C
-
-
Querétaro
-
Querétaro City、Querétaro、メキシコ、76000
- Cuidados oncologicos
-
-
-
-
Moscow Oblast
-
Moscow、Moscow Oblast、ロシア、143422
- MEDSI Clinical Hospital on Pyatnitsky Highway
-
Moscow、Moscow Oblast、ロシア、105229
- Main Military Clinical Hospital named after N.N. Burdenko
-
-
Sankt-Peterburg
-
Saint Petersburg、Sankt-Peterburg、ロシア、194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg、Sankt-Peterburg、ロシア、189646
- Institute of Oncology
-
Saint Petersburg、Sankt-Peterburg、ロシア、197089
- St. Petersburg Med Univ
-
Saint Petersburg、Sankt-Peterburg、ロシア、197758
- St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
-
-
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
Changchun、中国、130021
- The First Hospital of Jilin University
-
Chengdu、中国、610041
- West China Hospital, Sichuan University
-
Chongqing、中国、400030
- Chongqing Cancer Hospital
-
Fuzhou、中国、350014
- Fujian Cancer Hospital
-
Haikou、中国、570311
- Hainan General Hospital
-
Hangzhou、中国、310016
- Sir Run Run Shaw Hospital Zhejiang University
-
Harbin、中国、150081
- Harbin Medical University Cancer Hospital
-
Jinan、中国、250013
- Jinan Central Hospital
-
Meizhou、中国、514031
- Meizhou People's Hospital
-
Nanchang、中国、330200
- The 1st Affiliated Hospital of Nanchang Unversity
-
Nantong、中国、226361
- Nantong Tumor Hospital
-
Shanghai、中国、200433
- Shanghai Pulmonary Hospital
-
Shanghai、中国、200032
- Zhongshan Hospital Fudan University
-
Shanghai、中国、200120
- Fudan University Shanghai Cancer Center
-
Wuhan、中国、430022
- Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
-
Xi'an、中国、710061
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
Zhejiang、中国、310022
- Zhejiang Cancer Hospital
-
-
-
-
-
Guishan Dist.、台湾、33305
- Chang Gung Memorial Hospital - Linkou Branch
-
Kaohsiung City、台湾、83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City、台湾、807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City、台湾、23561
- Taipei Medical University ?Shuang Ho Hospital
-
Taichung、台湾、407
- Taichung Veterans General Hospital
-
Tainan、台湾、704
- National Cheng Kung Uni Hospital
-
Taipei、台湾、112
- Taipei Veterans General Hospital
-
Zhongzheng Dist.、台湾、10048
- National Taiwan University Hospital
-
-
-
-
-
Aichi、日本、464-8681
- Aichi Cancer Center
-
Chiba、日本、277-8577
- National Cancer Center Hospital East
-
Fukuoka、日本、812-8582
- Kyushu University Hospital
-
Miyagi、日本、980-0873
- Sendai Kousei Hospital
-
Niigata、日本、951-8566
- Niigata Cancer Center Hospital
-
Osaka、日本、589-8511
- Kindai University Hospital
-
Osaka、日本、541-8567
- Osaka International Cancer Institute
-
Saitama、日本、362-0806
- Saitama Cancer Center
-
Sakaishi、日本、591-8555
- NHO Kinki-Chuo Chest Medical Center
-
Shizuoka、日本、411-8777
- Shizuoka Cancer Center
-
Tokyo、日本、104-0045
- National Cancer Center Hospital
-
Tokyo、日本、135-8550
- The Cancer Institute Hospital of JFCR
-
-
-
-
-
Cheongju-si、韓国、28644
- Chungbuk National University Hospital
-
Gyeonggi-do、韓国、13620
- Seoul National University Bundang Hospital
-
Gyeonggi-do、韓国、16499
- Ajou University Medical Center
-
Incheon、韓国、21565
- Gachon University Gil Medical Center
-
Jeollanam-do、韓国、58128
- Chonnam National University Hwasun Hospital
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、03722
- Severance Hospital, Yonsei University Health System
-
Seoul、韓国、08308
- Korea University Guro Hospital
-
Seoul、韓国、6351
- Samsung Medical Center
-
Seoul、韓国、03181
- Kangbuk Samsung Medical Center
-
Suwon、韓国、442-723
- St. Vincent's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
- No prior systemic treatment for metastatic NSCLC
- High tumor tissue PD-L1 expression
- Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Adequate hematologic and end-organ function
- For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.
Exclusion Criteria:
- Known mutation in the EGFR gene or an ALK fusion oncogene
- Symptomatic, untreated, or actively progressing central nervous system metastases
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
- Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Severe infection within 4 weeks prior to initiation of study treatment
- Positive test result for human immunodeficiency virus (HIV)
- Active hepatitis B or hepatitis C
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Tiragolumab + Atezolizumab
Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity. |
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
他の名前:
Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
他の名前:
|
|
プラセボコンパレーター:Placebo + Atezolizumab
Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity. |
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
他の名前:
Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
時間枠:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
|
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
時間枠:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
|
Global Cohort: Overall Survival (OS) in the PAS
時間枠:From randomization to death from any cause (up to approximately 54.7 months)
|
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 54.7 months)
|
|
China Cohort: OS in the PAS
時間枠:From randomization to death from any cause (up to approximately 49.1 months)
|
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 49.1 months)
|
|
Global Cohort: Number of Participants With Adverse Events (AEs)
時間枠:Up to 65.1 months
|
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to 65.1 months
|
|
China Cohort: Number of Participants With AEs
時間枠:Up to 49.3 months
|
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to 49.3 months
|
|
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
時間枠:Up to 65.1 months
|
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS. |
Up to 65.1 months
|
|
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
時間枠:Up to 49.3 months
|
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS. |
Up to 49.3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
時間枠:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
|
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
時間枠:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
|
Global Cohort: OS in the SAS
時間枠:From randomization to death from any cause (up to approximately 54.7 months)
|
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 54.7 months)
|
|
China Cohort: OS in the SAS
時間枠:From randomization to death from any cause (up to approximately 49.1 months)
|
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 49.1 months)
|
|
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
時間枠:Up to approximately 54.6 months
|
Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off. |
Up to approximately 54.6 months
|
|
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
時間枠:Up to 49.3 months
|
Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off. |
Up to 49.3 months
|
|
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
時間枠:From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
|
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR. |
From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
|
|
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
時間枠:From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
|
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR. |
From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
|
|
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
時間枠:At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
時間枠:At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
時間枠:At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
時間枠:At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
時間枠:At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
時間枠:At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
時間枠:At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
時間枠:At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
時間枠:Up to approximately 54.6 months
|
TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 54.6 months
|
|
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
時間枠:Up to approximately 49.3 months
|
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 49.3 months
|
|
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
時間枠:Up to approximately 54.6 months
|
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 54.6 months
|
|
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
時間枠:Up to approximately 49.3 months
|
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 49.3 months
|
|
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
時間枠:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
|
|
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
時間枠:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
|
|
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
時間枠:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
|
|
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
時間枠:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
|
|
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
時間枠:Up to approximately 54.6 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 54.6 months
|
|
China Cohort: Number of Participants With ADAs to Tiragolumab
時間枠:Up to approximately 49.3 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 49.3 months
|
|
Global Cohort: Number of Participants With ADAs to Atezolizumab
時間枠:Up to approximately 54.6 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 54.6 months
|
|
China Cohort: Number of Participants With ADAs to Atezolizumab
時間枠:Up to approximately 49.3 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 49.3 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Trial、Hoffmann-La Roche
出版物と役立つリンク
一般刊行物
- Peters S, Herbst R, Horinouchi H, Paz-Ares L, Johnson M, Solomon BJ, Gumus M, Erman M, Bondarenko I, Kim DW, Felip E, Morabito A, Bryl M, Urban L, Nosaki K, Reck M, Meng R, Stroud C, Kundu P, Wen X, Patil NS, Huang M, Troutman S, Matheny C, Cho BC. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Sep;44(25):2400-2408. doi: 10.1200/JCO-25-02777. Epub 2026 Jul 27.
- Beaufils A, De Martino J, Jiang X, Blanchard T, Fraunhoffer N, Mendes D, Pignolet C, Bourega T, Meneghetti AR, Sainath S, Albuquerque M, Colnot N, Tihy M, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lecomte T, Biagi J, Artru P, Evesque L, Lambert A, Renouf DJ, Mauduit M, Dusetti NJ, Hammel P, Conroy T, Bachet JB, de Mestier L, Rebours V, Cros J, Kather JN, Nicolle R. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. J Clin Oncol. 2026 Sep 10;44(26):2507-2516. doi: 10.1200/JCO-26-00327. Epub 2026 Jul 27.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- GO41717
- 2019-002925-31 (EudraCT番号)
- 2019 (米国 NIH グラント/契約)
- 2022-502482-17-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。